GGK has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer, Sandoz, and Pendophram; received grants for research from Ferring; received grants for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer, and Takeda; and shares ownership of a patent for treatment of inflammatory disorders, autoimmune disease, and PBC (UTI Limited Partnership, assignee; Patent WO2019046959A1; PCT/CA2018/051098; Sept 7, 2018). CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, and Roche; speaker's fees from AbbVie, Amgen, AVIR Pharma Inc, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; and research support from Ferring and Pfizer. RP has received consulting fees, speaker's fees, and research support from AbbVie, Abbott, Alimentiv (formerly Robarts), Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresnius Kabi, Galapagos, Genentech, Gilead Sciences, Glaxo-Smith Kline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, UCB, and Takeda Pharmaceuticals. All other authors declared no competing interests. The work reported here was supported by a Canadian Institutes of Health Research Operating Grant (COVID-19 Rapid Research Funding Opportunity VR5-172684), Crohn's and Colitis Canada, the Public Health Agency of Canada through the Vaccine Surveillance Reference Group (VSRG) and the COVID-19 Immunity Task Force (CITY), and the Leona M and Harry B Helmsley Charitable Trust (grant G-2209-05501). JQ and AM are joint first authors.